ivabradine / Generic mfg. - LARVOL DELTA

Comparative Effectiveness of Ivabradine Versus Digoxin in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease: A Real-World Multicenter Cohort Study. (PubMed, Cardiorenal Med) - "In this large, real-world cohort of patients with HFrEF and CKD, ivabradine was associated with lower risks of MACE, HFE, and all-cause mortality compared with digoxin. Ivabradine may represent a safer and more effective heart-rate-lowering option for this high-risk population."

HEOR • Journal • Real-world evidence • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Nephrology • Renal Disease

IRISS: Ivabradine for Heart Rate Control In Septic Shock (clinicaltrials.gov) - P3 | N=429 | Active, not recruiting | Sponsor: Assistance Publique - Hôpitaux de Paris | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2024 ➔ Apr 2026 | Trial primary completion date: Sep 2024 ➔ Feb 2026

Enrollment closed • Trial completion date • Trial primary completion date • Congestive Heart Failure • Septic Shock

Potential use of ivabradine in postoperative junctional ectopic tachycardia: a systematic review and single-arm meta-analysis. (PubMed, BMC Cardiovasc Disord) - No abstract available

Journal • Retrospective data • Review • Cardiovascular • Ventricular Tachycardia

606. Meet the Trialists II (ACC 2026) - "This After Chat session takes an in-depth look at trails from Featured Clinical Research sessions 201 and 216, specifically: Impact Of Ivabradine On Orthostatic Intolerance, Quality Of Life And Heart Rate In Post-covid Postural Orthostatic Tachycardia Syndrome: Results From The Recover-Autonomic Trial Coronary Optical Coherence Tomography And Cardiac Magnetic Resonance Imaging To Determine Sex Differences In Underlying Causes Of Myocardial Infarction With No Obstructive Coronary Arteries Community-to-clinic Linkage Implementation Program To Prevent Hypertension In Barbershops"

Cardiovascular • Hypertension • Myocardial Infarction • Novel Coronavirus Disease

Impact Of Ivabradine On Orthostatic Intolerance, Quality Of Life And Heart Rate In Post-covid Postural Orthostatic Tachycardia Syndrome: Results From The Recover-Autonomic Trial (ACC 2026) - "Abstract is embargoed at this time."

HEOR • Late-breaking abstract • Cardiovascular • Novel Coronavirus Disease

BIOPROSTHETIC MITRAL VALVE THROMBOSIS WITH SEVERE HEMODYNAMIC COMPROMISE DESPITE DIRECT ORAL ANTICOAGULANT THERAPY (ACC 2026) - "Decision-Making: Despite compliance with apixaban therapy, thrombosis developed, resulting in pre- and post-capillary pulmonary hypertension. Management required balancing diuresis for pulmonary edema and maintaining diastolic preload with ivabradine in the setting of mitral stenosis... Bioprosthetic MV thrombosis with hemodynamic compromise can occur despite DOAC therapy. Consideration of vitamin K antagonists over DOACs in high-risk patients with bioprosthetic MVs and additional thromboembolic risk factors may be beneficial."

Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Thrombosis

COMPARATIVE EFFECTIVENESS OF VERICIGUAT VS IVABRADINE IN HEART FAILURE WITH REDUCED EJECTION FRACTION: A PROPENSITY SCORE-MATCHED ANALYSIS (ACC 2026) - "In this large, real-world propensity-matched analysis of HFrEF patients, vericiguat demonstrated superior effectiveness compared to ivabradine, with significant reductions in both mortality and all-cause hospitalization. These findings suggest vericiguat may provide greater clinical benefit than ivabradine in HFrEF management, though further randomized controlled trials are warranted to confirm these observational findings and establish optimal treatment sequencing."

HEOR • Cardiovascular • Congestive Heart Failure • Heart Failure

EVALUATION OF IVABRADINE INITIATION IN AN ACUTE CARE SETTING, A RETROSPECTIVE REVIEW OF ITS OFF LABEL USES (ACC 2026) - "The results will be discussed."

Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Septic Shock

SEX INEQUITIES IN EVIDENCE-BASED THERAPY FOR NEWLY DIAGNOSED HEART FAILURE WITH REDUCED EJECTION FRACTION: A REAL-WORLD ANALYSIS (ACC 2026) - "Outcomes included initiation of beta-blockers, ACEi/ARBs/ARNI, SGLT2 inhibitors, mineralocorticoid receptor antagonists (MRAs), ivabradine, implantable cardioverter defibrillator/cardiac resynchronization therapy (ICD/CRT), and cardiac rehabilitation at 1, 3, and 6 months... In this large real-world cohort, females with newly diagnosed HFrEF were consistently undertreated across GDMT classes, device therapy, and cardiac rehabilitation compared with males. These persistent disparities underscore the need for targeted quality improvement and policy interventions to achieve equity in the delivery of life-saving therapies."

Clinical • Real-world • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure

SAFETY OUTCOMES OF PERIOPERATIVE IVABRADINE USE IN SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (ACC 2026) - "Perioperative IVA use is not associated with a reduced risk of perioperative myocardial injury, bradycardia, or post-operative atrial fibrillation. It may be associated with a slightly increased risk of IO hypotension. However, more randomized controlled studies are needed to further investigate safety outcomes and validate this conclusion."

Retrospective data • Review • Surgery • Atrial Fibrillation • Cardiovascular • Hypotension

Cost-effectiveness of Add-On Ivabradine Versus Standard Pharmacotherapy in the Treatment of Heart Failure in Vietnam: An Analysis From a Health System Perspective. (PubMed, Value Health Reg Issues) - "From a Vietnamese health system perspective, adding ivabradine to standard pharmacotherapy is likely to be a cost-effective strategy for treating eligible patients with HF. This evidence supports value-based pricing in price negotiations and efficient resource use."

HEOR • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Personalized management of angina and heart failure in clinical practice in the Middle East: a narrative review. (PubMed, J Comp Eff Res) - "Clinicians should consider adding newer antianginal agents (long-acting nitrates, ranolazine, trimetazidine, ivabradine) to beta-blockers + calcium-channel blockers based on patient risk factors. In patients with HF with reduced ejection fraction in sinus rhythm and elevated heart rate, ivabradine should be added to maximum tolerated doses of beta-blockers. Adding ivabradine to first-line therapy improves heart rate control and QoL, and reduces HF-related hospitalization and mortality."

Journal • Review • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Myocardial Infarction

The Evolving Role of Ivabradine for Focal Atrial Tachycardia: A Systematic Review. (PubMed, J Arrhythm) - "Evidence from small cohorts and case reports suggests promising outcomes and a good safety profile of ivabradine for FAT, but larger, well-designed and more robust studies are needed. Recognizing an automaticity-driven FAT is key to considering ivabradine, especially when FAT persists despite cardioversion or standard therapy."

Journal • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure

Cardiac drug potential: exploring individual and combined cardiac drugs to promote differentiation of adipose-derived stem cells into cardiomyocytes. (PubMed, Mol Biol Rep) - No abstract available

Journal

A Prospective Clinical Audit to Improve Compliance With Perioperative Atrial Fibrillation Prevention Protocols in Off-Pump Coronary Artery Bypass Surgery. (PubMed, Cureus) - "Bisoprolol was the institutional beta-blocker; ivabradine was used if beta-blockers were contraindicated. Conclusion Structured, multidisciplinary quality-improvement measures significantly improved compliance with AF prevention protocols and were associated with a decrease in postoperative AF incidence by 50% in OPCAB patients. Routine audits and sustained adherence to protocol are recommended."

Compliance • Journal • Atrial Fibrillation • Cardiovascular

Expanding Beyond Foundational GDMT: Adjunctive Pharmacological Agents to Curb Transition From Stage C to D (ISHLT 2026) - "This presentation will review the landscape of medical therapies that may serve as an adjunct to the traditional four-tier GDMT for HfrEF, with a focus on their incremental impact on risk reduction. In particular focused will be on the use of ARNI for advanced heart failure, as well as the integration of SGLT2 inhibitors, vericiguat, ivabradine, GLP-1agonists into contemporary treatment strategies."

Cardiovascular • Congestive Heart Failure • Heart Failure

Acute Hemodynamic Effects of Ivabradine in Pediatric Cardiac Critical Care Patients. (PubMed, Am J Ther) - "Ivabradine seems safe in pediatric patients. It is associated with 3 distinct hemodynamic response phases: the first phase is associated with decreased heart rate and unchanged systemic oxygen delivery, the second phase is associated with increased heart rate and worsened systemic oxygen delivery, and the third phase being associated with decreased heart rate and improved systemic oxygen delivery. These phases coincide with the pharmacokinetic properties of ivabradine."

Journal • Cardiovascular • Congestive Heart Failure • Critical care • Heart Failure • Pediatrics

Heart rate control: Betablockers or Ivabradine therapy before cardiac computed tomography (clinicaltrialsregister.eu) - P4 | N=350 | Recruiting | Sponsor: Region Midtjylland

New P4 trial • Cardiovascular • Coronary Artery Disease • Heart Failure

The role of Ivabradine in hospitalized acute decompensated heart failure patients: a single center retrospective study (HEART FAILURE 2026) - No abstract available

Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure

RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine) (clinicaltrials.gov) - P2 | N=181 | Completed | Sponsor: Kanecia Obie Zimmerman | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

Design and rationale of RECOVER-AUTONOMIC: a randomized platform trial evaluating interventions for Long COVID postural orthostatic tachycardia syndrome. (PubMed, Am Heart J) - P2 | "RECOVER-AUTONOMIC seeks to determine the benefits and risks of IVIG and of ivabradine, as well as of coordinated nonpharmacologic care, for the treatment of POTS in Long COVID. Results from this trial will offer the largest source of evidence to help guide the medical care of this population."

Clinical • Journal • Cardiovascular • Hypotension • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Pharmacy Technician Impact on Access to High-Cost Heart Failure Pharmacotherapy. (PubMed, Ann Pharmacother) - "This study demonstrated a significant increase in access to sacubitril-valsartan and/or SGLT2i after the implementation of a pharmacy technician. Larger, prospective studies are needed to evaluate the impact of a pharmacy technician on clinical outcomes in this population."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Transplantation

Autonomic neurotransmission in cardiovascular regulation and pathophysiology. (PubMed, Front Neurosci) - "Pharmacologic interventions, such as β-blockers and ivabradine, alongside non-pharmacologic approaches, including structured exercise and respiratory training, aim to restore autonomic balance and improve clinical outcomes. Understanding the exact mechanisms of autonomic neurotransmission is essential for identifying novel therapeutic targets and optimizing cardiovascular care. Future research integrating molecular, genetic, and systems-level analyses will further elucidate autonomic regulation, guiding personalized interventions to mitigate cardiovascular morbidity and mortality."

Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Pain • Solid Tumor

Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC) (clinicaltrials.gov) - P3 | N=20 | Completed | Sponsor: University Hospital, Rouen | Unknown status ➔ Completed | N=30 ➔ 20

Enrollment change • Trial completion

Endocardial ablation-resistant ivabradine-sensitive atrial tachycardia suggestive of an epicardial origin in the left atrial appendage. (PubMed, J Cardiol Cases) - "Some focal atrial tachycardias (ATs) refractory to conventional antiarrhythmic drug therapy are successfully treated by ivabradine and are called ivabradine sensitive-ATs (ISATs). ISATs originating from the left atrial appendage (LAA) have been reported to be eliminated by endocardial radiofrequency ablation, but a subset of LAA-ISATs may be associated with epicardial abnormal automaticity and may be refractory to endocardial radiofrequency ablation."

Journal • Cardiomyopathy • Cardiovascular